BiotechTube
Home/Pharvaris/David Nassif, J.D.
DN

David Nassif, J.D.

Chief Financial Officer

Pharvaris

Therapeutic Areas

Rare DiseasesImmunologyAllergy

Pharvaris Pipeline

DrugIndicationPhase
Deucrictibant (PHVS719, XR tablet)Prophylactic treatment of Hereditary Angioedema (HAE) attacksPhase 3
Deucrictibant (PHVS416, IR capsule)On-demand treatment of Hereditary Angioedema (HAE) attacksPhase 3
DeucrictibantProphylactic & On-demand treatment of Acquired Angioedema due to C1-INH deficiency (AAE-C1INH)Phase 3

Leadership Team at Pharvaris

BM
Berndt Modig
Chief Executive Officer, Director
SA
Stefan Abele, Ph.D.
Chief Technical Operations Officer
AD
Annick Deschoolmeester
Chief Human Resources Officer
AL
Anne Lesage, Ph.D.
Chief Early Development Officer
PL
Peng Lu, M.D., Ph.D.
Chief Medical Officer
WS
Wim Souverijns
Chief Commercial Officer
MM
Marcus Maurer, M.D.
Scientific Advisor / Key Opinion Leader (inferred)
MA
Marc A. Riedl, M.D.
Scientific Advisor / Key Opinion Leader (inferred)
View full Pharvaris profile